检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]广州医学院第二附属医院心血管内科,广州心血管疾病研究所 [2]广州医学院生理教研室,广州510182
出 处:《广东医学》2011年第3期281-283,共3页Guangdong Medical Journal
基 金:广东省医学科学技术研究基金资助项目(编号:A2006298)
摘 要:目的研究钙调神经磷酸酶(CaN)信号途径在经皮血管成形术(percutaneous translum inal angiop las-ty,PTA)后再狭窄血管中的表达,探讨该途径在血管再狭窄发生中的作用。方法雄性SD大鼠16只,随机分为对照组(n=10)和实验组(n=6)。实验组球囊损伤术后30 d取材,对照组仅行颈部正中切开,正常喂饲30 d后取材,血管组织作HE染色,免疫组化检测CaN在血管壁中的表达,光学显微镜观察病理学改变。Real-tim e PCR法检测血管组织中CaN和活化T细胞核因子c3(NFATc3)的表达。结果球囊损伤后血管壁出现新生内膜,形成的新生内膜厚度不均;实验组与对照组比较,内膜厚度、内膜/中膜厚度明显增加(P<0.05);免疫组化检测实验组血管壁上CaN表达明显增强,与对照组比较差异有统计学意义(P<0.05);实验组血管壁组织CaN、NFATc3表达明显升高,与对照组比较差异有统计学意义(P<0.05)。结论球囊损伤后血管组织中CaN及其下游NFATc3表达增加,提示该途径参与PTA术后血管再狭窄的形成。Objective To investigate roles of the CaN -NFATc signal transduetion pathway in the restenosis following percutaneous transluminal angioplasty. Methods Sixteen healthy adult male SD rats were randomly divided into two groups: sham operation group (n = 10) and balloon group (n = 6). Specimens were obtained for pathological and CaN expression observation with HE staining and immunohistochemistry, respectively, 30 days after balloon injury. The expression of CaN and NFATe3 in abdominal aortas was measured by real - time PCR, Results Intimal hyperplasia with various neointima thickness was observed in balloon group. Significantly lower ratio of intimal layer to medial layer and expression level of CaN were observed in sham operation group than that in balloon group (P 〈 O. 05 ). Significant higher expression of calcineurin and NFATe3 in arterial wall was detected in balloon injury group according to RT - PCR (P 〈 0. 05 ). Conclusion The expression of calcineurin and NFATc3 mRNA increases significantly after balloon injury, suggesting that CaN - NFATc signal transduetion pathway plays a role in restenosis after PTA.
分 类 号:R256.1[医药卫生—中医内科学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.188.39.197